Biologics Linked to Faster Steroid Tapering in RA
A Hong Kong registry study compared glucocorticoid discontinuation rates among rheumatoid arthritis patients starting different targeted drug classes.
Updated on Nov. 2, 2026 in Arthritis
A retrospective study published September 23, 2026, in Seminars in Arthritis and Rheumatism analyzed Hong Kong registry data on adults with rheumatoid arthritis. Patients starting certain biologic agents had lower odds of discontinuing glucocorticoids than those starting JAK inhibitors.
Why it matters
Glucocorticoids are widely used to control rheumatoid arthritis symptoms but carry long-term risks, so the timing of steroid withdrawal matters for patient safety. The findings suggest drug choice may influence how quickly patients can reduce steroid reliance.
The analysis covered 1,421 patients, with a median age of 57 and 81.8% women, showing discontinuation rates of 26.2% at three months and 36.8% at six months. Anti-TNF agents were associated with 48.0% lower odds and anti-CD20 agents with 86.6% lower odds of discontinuation at three months versus JAK inhibitors, though the observational design leaves causality unconfirmed.
The players
Seminars in Arthritis and Rheumatism
A peer-reviewed clinical journal that publishes research on rheumatic and musculoskeletal diseases, where the study was released.
The details
Researchers reviewed patients in the Hong Kong registry who began a first-ever biologic or targeted synthetic disease-modifying antirheumatic drug between January 2006 and December 2021 while also taking glucocorticoids. The authors called for better education for healthcare professionals and patients about glucocorticoid use in rheumatoid arthritis.
Timeline
January 2006 to December 2021: Patients began their first-ever biologic or targeted synthetic DMARD in the Hong Kong registry.
September 23, 2026: Study published online in Seminars in Arthritis and Rheumatism.
Big Picture
The findings add real-world registry evidence to the ongoing debate over how biologics and JAK inhibitors compare for steroid-sparing in rheumatoid arthritis. They extend that debate into a Hong Kong cohort where patients were predominantly women and treated in routine clinical practice.
Patients taking steroids alongside rheumatoid arthritis medication may want to discuss with their clinicians how quickly steroid use can be reduced. Treatment choice may affect how soon that reduction is possible.
The takeaway
Choice of targeted therapy may influence how quickly people with rheumatoid arthritis can reduce glucocorticoids. Clinicians and patients are encouraged to review steroid plans regularly as treatment begins.
Further reading
Explore more on Arthritis to see how treatment choices shape long-term disease management.
Source note: This article includes information reported by Medscape.
